Aviva PLC Makes New $539,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Aviva PLC purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 31,427 shares of the biotechnology company’s stock, valued at approximately $539,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ADMA. GAMMA Investing LLC increased its holdings in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the period. National Bank of Canada FI bought a new position in shares of ADMA Biologics in the third quarter worth $35,000. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of ADMA Biologics in the fourth quarter worth $35,000. Vision Financial Markets LLC bought a new stake in ADMA Biologics during the fourth quarter valued at $51,000. Finally, AlphaQuest LLC purchased a new position in ADMA Biologics during the fourth quarter worth about $84,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $19.40 on Friday. ADMA Biologics, Inc. has a 52-week low of $5.91 and a 52-week high of $23.64. The company has a fifty day moving average of $17.78 and a 200-day moving average of $18.16. The company has a market capitalization of $4.59 billion, a P/E ratio of 69.29 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.